-
Autifony is developing modulators of an ion channel to improve the brain's auditory processing and mitigate permanent hearing loss or tinnitus associated with cochlear damage.
Published on 6/17/2013
-
Autifony: Sense and sensitivity Autifony Therapeutics Ltd. London, U.K. Technology: Compounds targeting Kv3 voltage-gated ion channels Disease focus: Neurology Clinical status: Phase I Founded: 2011 by Charles …
Published on 6/17/2013
-
Trino spun out of Trinity College Dublin with a portfolio of novel anti-inflammatory compounds that have shown potential in preclinical models of ulcerative colitis.
Published on 6/17/2013
-
Trino: Planting GI health Trino Therapeutics Ltd. Dublin, Ireland Technology: Dimeric indane-based scaffold molecules derived from a Taiwanese fern Disease focus: Inflammation, autoimmune, gastrointestinal …
Published on 6/17/2013
-
ONL Therapeutics: Eyeing Fas ONL Therapeutics LLC Ann Arbor, Mich. Technology: Peptide antagonist of Fas-mediated apoptosis for ophthalmic use Disease focus: Ophthalmic Clinical status: Preclinical Founded: 2011…
Published on 6/10/2013
-
ONL's Fas antagonist may be the first pharmacotherapy to prevent vision loss in non-exudative retinal detachment. It could complement existing ophthalmic therapies by blocking the sole pathway of photoreceptor death
Published on 6/10/2013
-
Cyteir: Stopping shape-shifters Cyteir Therapeutics Inc. Hinsdale, Ill. Technology: Small molecules targeting DNA repair Disease focus: Cancer Clinical status: Preclinical Founded: 2012 by Kevin Mills, Tim …
Published on 6/3/2013
-
Cyteir is developing small molecule inhibitors of RAD51, a DNA repair enzyme used by many chronic lymphocytic leukemias.
Published on 6/3/2013
-
Calypso: Fistula fix Calypso Biotech S.A. Geneva, Switzerland Technology: mAbs to treat gastrointestinal-related autoimmune diseases Disease focus: Autoimmune Clinical status: Preclinical Founded: 2013 by …
Published on 5/27/2013
-
Calypso expects its antibodies will be able to treat the underlying inflammation in patients with Crohn's disease, as well as the fibrotic complications that marketed therapies don't address.
Published on 5/27/2013
-
Numab's bispecific mAb program has the potential to provide greater efficacy by eliminating T cells vs. approaches that block T cell differentiation.
Published on 5/27/2013
-
Numab: Safely Killing T Cells Numab AG Waedensil, Switzerland Technology: Mono- and bispecific antibody fragment-based discovery Disease focus: Autoimmune Clinical status: Discovery Founded: 2011 by David Urech,…
Published on 5/27/2013
-
Galileo: A TALL order Galileo Research S.r.L. Pisa, Italy Technology: Allogeneic stem cell therapy Disease focus: Cancer Clinical status: Phase II Founded: 2011 by Massimo Di Martino University collaborators: …
Published on 5/20/2013
-
Galileo's allogeneic immunotherapy mimics natural killer cells, but they spare healthy cells and could have broader activity than off-the-shelf cancer vaccines in development.
Published on 5/20/2013
-
With a pair of compounds acquired from an Indian pharma, Allecra aims to develop a broad-spectrum solution to multidrug resistant Gram-negative bacteria.
Published on 5/13/2013
-
Allecra: Secret weapon vs. bacteria Allecra Therapeutics GmbH Lorrach, Germany Technology: Antimicrobials for drug-resistant bacteria Disease focus: Infectious Clinical status: Preclinical Founded: 2013 by …
Published on 5/13/2013
-
Ultimovacs: hTERT redux Ultimovacs AS Oslo, Norway Technology: Peptide-based therapeutic cancer vaccines Disease focus: Cancer Clinical status: Phase I/IIa Founded: 2011 by Gustav Gaudernack, Else Marit …
Published on 5/13/2013
-
Ultimovacs is developing a telomerase-based cancer vaccine that could treat a much broader range of cancer patients than a first-generation vaccine now in the clinic.
Published on 5/13/2013
-
Neurotrope: Saving synapses Neurotrope BioScience Inc. Plantation, Fla. Technology: Small molecule activators of protein kinase C isozymes Disease focus: Neurology Clinical status: Phase II Founded: 2012 by John…
Published on 5/6/2013
-
Neurotrope is developing Alzheimer's therapeutics targeting protein kinase C, an enzyme that could play a central role in pathology upstream of amyloid plaques and neurofibrillary tangles.
Published on 5/6/2013
-
Avilex: One-two pain punch Avilex Pharma ApS Copenhagen, Denmark Technology: Dimeric inhibitor of PSD95 Disease focus: Neurology Clinical status: Preclinical Founded: 2013 by Anders Bach and Kristian Stromgaard…
Published on 4/29/2013
-
Avilex's dimeric inhibitor of PSD95 could offer a potent treatment for chronic pain without cognitive side effects of other approaches in NMDA pathway.
Published on 4/29/2013
-
TissUse: Human on a chip TissUse GmbH Berlin, Germany Technology: Chip that contains organoids Disease focus: Microtissue arrays Clinical status: Preclinical Founded: 2010 by Uwe Marx, Gerd Lindner, Heike Walles…
Published on 4/29/2013
-
TissUse is developing a chip that contains multiple miniature organoids that might supplement or replace some preclinical and clinical testing.
Published on 4/29/2013
-
Cardiorentis is the fifth company to try ularitide for acute heart failure. It expects to succeed thanks to a big war chest and reduced clinical trial requirements in the EU.
Published on 4/22/2013